On April 16, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization for bamlanivimab, when administered alone, due to a sustained increase in COVID-19 viral variants in the U.S. that are resistant to this antibody therapy. The FDA determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks. Medicare will cover and pay for bamlanivimab, when administered alone, for dates of service from Nov. 10, 2020 – April 16, 2021.
Web link Date Added: 04/20/2021
Date Last Modified: Apr 20 2021 6:05PM